Objective: This study identified variables associated with increased risk of atrial fibrillation in people with type 1 diabetes.
Research Design And Methods: We performed a cohort study of people with type 1 diabetes from the Swedish National Diabetes Registry followed up between 1 January 2001 and 31 December 2013. Median follow-up was 9.7 years (interquartile range 5.2-13.0). The association between potential risk factors and incident atrial fibrillation was investigated using adjusted Cox regression. To compare the impact of each risk factor, the gradient of risk per 1 SD was estimated.
Results: In this cohort of 36,258 patients with type 1 diabetes, 749 developed atrial fibrillation during follow-up. Older age, male sex, renal complications, increased BMI and HbA, coronary artery disease, heart failure, and heart valve disease increased the risk of atrial fibrillation. Age, signs of renal dysfunction with macroalbuminuria, and decreasing estimated glomerular filtration rate were associated with the highest gradient of risk for atrial fibrillation. High blood pressure, severe obesity (BMI >35 kg/m), and elevated levels of HbA (>9.6%) were associated with increased risk, but no associations were found with hyperlipidemia or smoking.
Conclusions: The most prominent risk factors for atrial fibrillation in people with type 1 diabetes were older age, cardiovascular comorbidities, and renal complications, while obesity, hypertension, and hyperglycemia had more modest affects.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.2337/dc18-2457 | DOI Listing |
ESC Heart Fail
March 2025
Institute of Health Informatics Research, University College London, London, UK.
Aims: Atrial fibrillation (AF) is a frequent comorbidity in heart failure (HF). We analysed factors associated with new-onset atrial fibrillation in patients with heart failure using linked real-world UK data from primary and secondary care, along with findings from genome-wide association studies.
Methods And Results: Among 163 174 participants with a diagnosis of HF (January 1998 to May 2016) from Clinical Practice Research Datalink (CPRD) and Hospital Episodes Statistics (HES), 111 595 participants had no previous history of AF (mean age 76.
Chest
March 2025
Department of Intensive Care Medicine, Ningbo No.2 Hospital, Ningbo, Zhejiang, China.
A 71-year-old man with a history of atrial fibrillation presented to the emergency department with sudden unconsciousness after finishing lunch. Just 4 weeks ago, the patient underwent radiofrequency ablation for atrial fibrillation and regularly took rivaroxaban for anticoagulant therapy. According to the medical history, the patient suffered recurrent chest tightness and heartburn after radiofrequency ablation without other discomforts.
View Article and Find Full Text PDFCirc J
March 2025
Department of Preventive Cardiology, National Cerebral and Cardiovascular Center.
Background: The aim of this was to develop an atrial fibrillation (AF) risk score using items usually included in Japanese governmental health check-ups.
Methods And Results: We analyzed data from 6,476 Japanese participants registered in the Suita Study. At baseline, the participants were aged ≥30 years and were free from AF.
Can J Cardiol
March 2025
Department of Cardiology, Rabin Medical Center, Petah Tikva, Israel; The Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Background: The use of transcatheter aortic valve implantation (TAVI) for severe aortic stenosis is expanding to patients across the entire spectrum of surgical risk. We aimed to perform a meta-analysis comparing TAVI and surgical aortic valve replacement (SAVR) in trials enrolling lower risk patients.
Methods: We conducted a meta-analysis of randomized controlled trials (RCTs) comparing safety and efficacy outcomes between TAVI and SAVR among lower risk patients (mean/median STS score <4).
Int J Cardiol
March 2025
Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China. Electronic address:
Background: Pulsed-field ablation (PFA) emerges as an innovative nonthermal energy modality for catheter ablation of atrial fibrillation (AF). This study aimed to assess the safety and effectiveness of a novel PFA system that uses a multichannel, circular ablation catheter with adjustable diameters in treating paroxysmal AF.
Methods: This clinical trial (PF-Beat-AF) was a prospective, multicenter, single-arm study.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!